A prespecified BRIGHT-4 subgroup analysis finds bivalirudin reduces death or major bleeding versus heparin in lower-BMI STEMI patients but not higher-BMI, with a significant interaction. PICO summary and commentary.
Browsing: Cardiovascular
Cardiovascular outcomes, heart failure, cardio-renal protection, hypertension, and lipid-lowering trials in diabetes and endocrinology.
A four-arm RCT finds exercise plus broccoli sprouts improves apolipoproteins in men with type 2 diabetes, but the benefit is mainly exercise-driven. PICO summary and commentary.
A small RCT finds a 12-week hybrid Tai Chi cardiac rehab programme reduces perceived stress and oxidised LDL more than conventional exercise in chronic coronary syndrome. PICO summary and commentary.
A lipidomics analysis from the randomised EmDia trial finds empagliflozin remodels plasma lipids in type 2 diabetes, raising beneficial LPCs but also harmful ceramides. PICO summary and commentary.
An OPTION post-hoc analysis finds indobufen-based antiplatelet therapy after stenting performs consistently regardless of diabetes status, with a similar bleeding advantage. PICO summary and commentary.
Summary: In adults with HFpEF (EF ≥50%), obesity (BMI ≥30 kg/m²), stratified by presence or absence of type 2 diabetes…
A prespecified SUMMIT analysis finds tirzepatide reduces heart-failure events in obese HFpEF regardless of diabetes status, despite less weight loss with diabetes. PICO summary and commentary.
Summary: In adults with uncontrolled type 2 diabetes in China, a mobile app-based intervention significantly improved HbA1c and systolic blood…
The 4-year DAPAHEART follow-up finds dapagliflozin raises coronary flow reserve by 34% and reduces epicardial fat, apparently independent of weight loss. PICO summary and commentary.
An RCT finds triple therapy with a statin, SGLT2 inhibitor, and PCSK9 inhibitor lowers lipids more than monotherapy in ischemic heart disease. PICO summary and commentary.